From the late 1980s, emerging evidence suggested that PAH patients have increased degradation of VWF and a decrease in high molecular weight multimers, and/or platelet dysfunction, which are typical findings of AVWS type 2 (27). The gene discussed is VWF; the disease is pulmonary arterial hypertension.